New to site?


Login

Lost password? (X)

Already have an account?


Signup

(X)
Farooq

AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia

HomeINDUSTRY NEWSAstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia
30
Oct
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia

AstraZenecaAstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in Europe and Russia.Original Article

Tags:

    Related Posts
    Leave A Comment

    Leave A Comment